Category Archives: Clinical Cardiology

November 7, 2019 There was no difference between drug-coated balloons (DCB) vs. plain old balloon angioplasty (POBA) following B-Laser atherectomy, according to late-breaking study results from the DCB Versus POBA After B-Laser Atherectomy Trial at the Vascular InterVentional Advances (VIVA) Annual Meeting Continue reading →

PRESIDENTIAL SESSION Tuesday, 12:45 pmThis years presidential session, with remarks by American Heart Association CEO Nancy Brown, will also feature select song performances by theater stars from the Broadway hit Hamilton. The Conner Presidential Address will be given by distinguished cardiologist Robert A. Harrington, and the Keynote Address will be delivered by Murat Sonmez of the World Economic Forum. Continue reading →

November 6, 2019 Boston Scientific announced positive data for two of its devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at Vascular Interventional Advances (VIVA) meeting in Las Vegas. Continue reading →

The U.S. Food and Drug Administration (FDA) division that handles new and existing oncology drugs was renamed and restructured. The agencys Center for Drug Evaluation and Research (CDER) Office of Hematology and Oncology Products (OHOP) is now the CDERs Office of Oncologic Diseases (OOD) Continue reading →

Study Highlights: News Release, American Heart Association DALLAS, Oct. Continue reading →

November 6, 2019 Positive, two-year data from the first-in-human study of Selution SLR, MedAlliances novel sirolimus-eluting balloon, was presented at VIVA 2019 by Principal Investigator Professor Thomas Zeller, M.D., Ph.D., Universitaets-Herzzentrum, Bad Krozingen, Germany. The study involved 50 patients treated with the investigational device in lesions of the superficial femoral artery (SFA) and popliteal artery. Continue reading →

November 7, 2019 Although the Abbott Absorb fully bioresorbable drug-eluting stent (DES) was taken off the market due to poor sales and questions on outcomes in coronary vessels compared to conventional metallic DES, it performed very well in peripheral vessels below the knee (BTK) in the ABSORB BTK Trial. The results were presented as a late-breaking trial at the 2019 Vascular Interventional Advances (VIVA) annual meeting. This novel bioresorbable, drug-eluting scaffold has several inherent advantages over stents, related to its biological resorption Continue reading →

Social needs including food, housing, utilities, transportation and exposure to interpersonal violence are well known to be linked to health outcomes. Continue reading →

The presence of epicardial coronary spasm and increased microvascular resistance in patients with angina but without obstructive coronary artery disease is associated with an increased risk of major adverse cardiovascular events, according to the results of a small study. Patients with coronary spasm and a high index of microcirculatory resistance (IMR) had a significantly worse prognosis compared with those without vasospasm and a normal IMR (HR 6.23; 95% CI 1.21-118.48) over a median follow-up of 893 days Continue reading →

DUBLIN--(BUSINESS WIRE)--The "Computed Tomography (CT) Scanners Devices And Equipment Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering. The global computed tomography (ct) scanners devices and equipment market was valued at about $6.9 billion in 2018 and is expected to grow to $8.04 billion at a CAGR of 3.9% through 2022. The Computed Tomography (CT) scanners devices and equipment market consists of sales of computed tomography (CT) scanners devices and equipment and related services Continue reading →